We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$478M
AUM Growth
+$56.7M
Cap. Flow
+$17.4M
Cap. Flow %
3.64%
Top 10 Hldgs %
53.49%
Holding
96
New
7
Increased
25
Reduced
16
Closed
12

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$13M
2
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$6.09M
3
OTIC
Otonomy, Inc.
OTIC
+$4.6M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.98M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.8M

Top Sells

Rank Stock Value
1
PLX icon
Protalix BioTherapeutics
PLX
+$5.37M
2
ATRC icon
AtriCure
ATRC
+$2.69M
3
ALEC icon
Alector
ALEC
+$2.57M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.36M
5
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
76
DELISTED
Masimo
MASI
$727K 0.15%
3,000
– –
GNFT
77
DELISTED
Genfit
GNFT
$716K 0.15%
188,549
– –
NGM
78
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$601K 0.13%
30,502
+20,502
+205% +$480K
MDGL icon
79
Madrigal Pharmaceuticals
MDGL
$11.8B
$545K 0.11%
5,600
– –
RDUS
80
DELISTED
Radius Health, Inc.
RDUS
$264K 0.06%
14,500
– –
SCPH
81
DELISTED
scPharmaceuticals
SCPH
$238K 0.05%
38,891
– –
CNTB
82
Connect Biopharma Holdings
CNTB
$132M
$156K 0.03%
8,000
– –
ACAD icon
83
Acadia Pharmaceuticals
ACAD
$4.57B
– –
-83,000
Closed -$2.14M
ALEC icon
84
Alector
ALEC
$173M
– –
-127,500
Closed -$2.57M
IRON icon
85
Disc Medicine
IRON
$3.01B
– –
-5,000
Closed -$2.03M
JNJ icon
86
Johnson & Johnson
JNJ
$612B
– –
-9,400
Closed -$1.54M
LCTX icon
87
Lineage Cell Therapeutics
LCTX
$284M
– –
-75,400
Closed -$177K
LQDA icon
88
Liquidia Corp
LQDA
$7.91B
– –
-575,000
Closed -$1.55M
PLX icon
89
Protalix BioTherapeutics
PLX
$192M
– –
-1,204,825
Closed -$5.37M
SCYX icon
90
SCYNEXIS
SCYX
$52M
– –
-11,234
Closed -$714K
VRNA
91
DELISTED
Verona Pharma
VRNA
– –
-18,337
Closed -$153K
XFOR icon
92
X4 Pharmaceuticals
XFOR
$407M
– –
-2,330
Closed -$602K
SPPI
93
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-197,500
Closed -$644K
AGTC
94
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-430,111
Closed -$2.18M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, DAFNA Capital Management held 96 positions worth $478M, up 13% from $421M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $17.4M of net new capital in Q2 2021, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.69M trimmed.

  • DAFNA Capital Management's largest Q2 2021 buy was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
  • DAFNA Capital Management added most to Theravance Biopharma in Q2 2021, an estimated $13M increase.
  • DAFNA Capital Management's biggest Q2 2021 reduction was AtriCure, cutting an estimated $2.69M.
  • DAFNA Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $5.37M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $478M portfolio in Q2 2021.
  • DAFNA Capital Management opened 7 new positions and closed 12 in Q2 2021.
  • DAFNA Capital Management's portfolio value rose 13% quarter-over-quarter to $478M.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.